Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?

Eloy, Philippine; Le Grand, Roger; Malvy, Denis; Guedj, Jérémie

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?

Eloy, Philippine; Le Grand, Roger; Malvy, Denis; Guedj, Jérémie.

Eloy P; INSERM CIC-EC 1425, Hôpital Bichat Claude Bernard, 75018 Paris, France.
Le Grand R; Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
Malvy D; Inserm, UMR 1219, Université de Bordeaux, Bordeaux, France; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Guedj J; Université de Paris, IAME, INSERM, F-75018 Paris, France. Electronic address: jeremie.guedj@inserm.fr.

EBioMedicine ; 74: 103663, 2021 Dec.

Article in English | MEDLINE | ID: covidwho-1664856

Subject(s)

Amides/therapeutic use; Antiviral Agents/therapeutic use; COVID-19 Drug Treatment; Cytidine/analogs & derivatives; Hydroxylamines/therapeutic use; Pyrazines/therapeutic use; SARS-CoV-2/drug effects; Animals; Cricetinae; Cytidine/therapeutic use; Drug Synergism; Drug Therapy, Combination; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Cytidine / Amides / SARS-CoV-2 / COVID-19 Drug Treatment / Hydroxylamines Limits: Animals / Humans Language: English Journal: EBioMedicine Year: 2021 Document Type: Article Affiliation country: J.ebiom.2021.103663

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google